Xencor Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.65 |
Market Cap |
$2.48 B |
Shares Outstanding |
56.35 M |
Public Float |
55.56 M |
Address |
111 West Lemon Avenue Monrovia California 91016 United States |
Employees | - |
Website | http://www.xencor.com |
Updated | 07/08/2019 |
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. |